Incidental papillary carcinoma of thyroid in Graves’ disease
Keywords:
Graves’ disease, TSH, Papillary carcinomaAbstract
Traditionally Grave's disease was considered as protection against thyroid cancer. The incidence of papillary carcinoma thyroid in grave’s disease is 2.4%. Thyroid cancer occurring in grave’s disease has higher frequency of persisting or relapsing disease than thyroid cancers occurring in matched euthyroid control patients. Here we present a case of papillary carcinoma in a Grave’s disease patient presented with nodular goiter.
Metrics
References
Shapiro SJ, Friedmann NB, Pezik SL, Catz B. Incidence of thyroid carcinoma in Graves' disease. Cancer. 1970;26:1261-70.
Farbota LM, Calandra DB, Lawrence AM, Paloyan E. Thyroid carcinoma in Graves' disease. Surgery 1985;98:1148-52.
Pellegriti G, Belfiore A, Giuffrida D, Lupo L, Vigneri R. Outcome of differentiated thyroid cancer in Graves’ patients. Journal of Clinical Endocrinology and Metabolism 1998;83:2805-9.
Roger P, Taton M, Van Sande J, Dumont JE. Mitogenic effects of thyrotropin and adenosine 30, 50-monophosphate in differentiated normal human thyroid cells in vitro. Journal of Clinical Endocrinology and Metabolism 1988;66:1158-65.
Filetti S, Belfiore A, Amir SM, Daniels GH, Ippolito O, Vigneri R, Ingbar SH. The role of thyroid-stimulating antibodies of Graves’ disease in differentiated thyroid cancer. New England Journal of Medicine 1988;318:753-9.
Ishikawa N, Eguchi K, Otsubo, et al. Reduction in the suppressor - inducer T- cell subset and increase in the helper T- cell subset in thyroid tissue from patients with Graves' disease. J Clin Endocrinol Metab. 1987;65:17-23.
Beahrs OH, Pemberton JDJ, Black BM. Nodular goiter and malignant lesions of the thyroid gland. J Clin Endocrinol. 1951;11:1157-65.
Sokal JE. Incidence of malignancy in toxic and nontoxic nodular goiter. JAMA. 1954;1541321-5.
